BioXcel Therapeutics (BTAI) PT Lowered to $95 at BMO Capital Aug 14, 2020 03:05PM
BioXcel Therapeutics (BTAI) PT Raised to $104 at BMO Capital; 'BXCL501 Clean SERENITY Data Supports Approval' Jul 20, 2020 01:46PM
BioXcel Therapeutics (BTAI) PT Raised to $64 at BMO Capital; 'Adding BXCL501 Opioid Withdrawal to Model' Mar 9, 2020 11:57AM
BioXcel Therapeutics (BTAI) Prices 2.3M Common Stock Offering at $8.25/Share Sep 26, 2019 09:12AM
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock Sep 26, 2019 09:11AM


Sep 25, 2019 04:27PM BioXcel Therapeutics (BTAI) Announces Proposed $19M Public Offering of Common Stock
Sep 25, 2019 04:27PM BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
Sep 18, 2019 09:39AM BioXcel Therapeutics (BTAI) To Launch Smartwatch Agitation Detection Study - BMO Capital
May 23, 2019 07:53AM BioXcel Therapeutics (BTAI) PT Raised to $21 at BMO Capital
Dec 3, 2018 06:00AM BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Jun 28, 2018 08:30AM BMO Capital Reiterates Outperform on BioXcel Therapeutics (BTAI)
Apr 2, 2018 04:23AM BMO Capital Starts BioXcel Therapeutics (BTAI) at Outperform
Mar 12, 2018 04:01PM BioXcel Therapeutics Announces Closing of Initial Public Offering
Mar 12, 2018 04:01PM BioXcel Therapeutics Announces Closing of Initial Public Offering
Mar 8, 2018 10:25AM BioXcel Therapeutics (BTAI) IPO Opens Flat
Feb 12, 2018 05:33PM BioXcel Therapeutics (BTAI) Files $69M IPO